Compare · MEDP vs PRAH
MEDP vs PRAH
Side-by-side comparison of Medpace Holdings Inc. (MEDP) and PRA Health Sciences, Inc. (PRAH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MEDP and PRAH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP carries a market cap of $18.29B.
- MEDP has hit the wire 3 times in the past 4 weeks while PRAH has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 0 for PRAH).
- Company
- Medpace Holdings Inc.
- PRA Health Sciences, Inc.
- Price
- -
- -
- Market cap
- $18.29B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2014
- News (4w)
- 3
- 0
- Recent ratings
- 25
- 0
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest MEDP
- SEC Form SCHEDULE 13G filed by Medpace Holdings Inc.
- General Counsel & Corp. Secy. Ewald Stephen P sold $859,050 worth of shares (1,245 units at $690.00), decreasing direct ownership by 6% to 19,098 units (SEC Form 4)
- Exec. VP, Operations Burwig Susan E sold $13,540,000 worth of shares (20,000 units at $677.00) (SEC Form 4)
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 10-Q filed by Medpace Holdings Inc.
- SEC Form 8-K filed by Medpace Holdings Inc.
- Medpace Holdings, Inc. Reports Third Quarter 2026 Results
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
Latest PRAH
- Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
- SEC Form SC 13G filed by PRA Health Sciences, Inc.
- SEC Form SC 13G/A filed by PRA Health Sciences, Inc. (Amendment)
- SEC Form 4: Gaenzle Christopher L returned 34,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: SHANNON COLIN returned 46,500 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Bonello Michael J. returned 4,480 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Young Matthew P. returned 7,127 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Stettin Glen D. returned 1,049 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: MOMTAZEE JAMES C returned 3,521 units of Common Stock to the company, closing all direct ownership in the company
- SEC Form 4: Dickinson Alexander George returned 5,407 units of Common Stock to the company, closing all direct ownership in the company